Brixadi®: 3 things to know about the buprenorphine treatment option

Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi^®, can help support the people you serve.

Overview on Brixadi

• Brixadi is an extended-release form of buprenorphine (an FDA-approved medication used to treat OUD that can be prescribed in physician offices) that continuously releases and sustains medicine levels throughout the month. It’s indicated for the treatment of moderate to severe OUD in patients who have initiated treatment with a single dose of transmucosal buprenorphine product or who are already being treated with buprenorphine.

How to offer and administer

• Brixadi is part of a Risk Evaluation and Mitigation Strategies (REMS) program, meaning that only certain pharmacies can dispense the medication directly to a healthcare provider. Brixadi can only be delivered to a prescriber’s DEA-registered address and may not be dispensed by a pharmacy directly to a patient. Genoa has over 300 locations certified to dispense Brixadi, and continues to certify additional sites every month. Connect with your local pharmacy team to learn more.

• Brixadi is injected subcutaneously into the subcutaneous tissue of the buttock, thigh, abdomen or upper arm. It is available as a pre-filled single-dose syringe with a 23-gauge ½ inch needle with an injection volume less than or equal to 0.64 mL.

• Brixadi does not need to be refrigerated and can be stored at room temperate at 68° F to 77° F with excursions permitted at 59° F and 86° F.

Barriers to receiving care

• Insurance/prior authorization: Brixadi is still being added to formularies. Your Genoa pharmacy team can assist with determining insurance coverage for Brixadi and can help with any prior authorizations that may be required.

• New treatment option: As a new medication, providers may not be familiar with the product and available dosing options for Brixadi. The Genoa pharmacy team can assist in educating your staff on how to offer Brixadi as a treatment option for the people you serve.

Connect with your local pharmacy team to learn more or fill out the form below and we’ll be in touch.

1: For information on Brixadi® prescirbing information: BRIXADI Prescribing Information (brixadihcp.com)

2. For general information on Brixadi®:  BRIXADI® (buprenorphine) injection for subcutaneous use is now available! (brixadihcp.com)